Advertisement

Topics

FDA Approves Rituxan Hycela for Subcutaneous Injection in Certain Blood Cancers

06:05 EDT 23 Jun 2017 | PharmPro

FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers. Treatment can be administered in five to seven minutes, compared to 1.5 hours or more for intravenous Rituxan.
Contributed Author: 
Genentech

Original Article: FDA Approves Rituxan Hycela for Subcutaneous Injection in Certain Blood Cancers

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Rituxan Hycela for Subcutaneous Injection in Certain Blood Cancers"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...